Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00349921 · ClinicalTrials.gov registry record · Phase 2
Clonidine Versus Adenosine to Treat Neuropathic Pain
A Phase 2 study of Pain, sponsored by Wake Forest University Health Sciences.
- Completed
- Registry status
- Phase 2
- Development phase
- 24
- Enrollment target
- 2
- Study locations
NCT00349921: Completed Phase 2 study of Pain, sponsored by Wake Forest University Health Sciences.
NCT00349921 is a Phase 2 study of Pain that has completed, run by Wake Forest University Health Sciences. The registered enrollment target is 24 participants, below the 304-participant average among 374 other Pain trials with a reported enrollment target (92% lower). The trial reports 2 study locations across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00349921, a Phase 2 study of Pain, has completed, sponsored by Wake Forest University Health Sciences.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 24 participants
- Enrollment target
- 2
- Study locations
Study Summary
The purpose of this study is to determine the effects of clonidine and adenosine on nerve pain.
Primary Outcome
Verbal pain report 2 hours post injection compared to baseline verbal pain scores prior to injection
Conditions Studied
Interventions
- DRUG placebo
- DRUG adenosine
- DRUG clonidine
Study Locations (2)
North Carolina
- The Center for Clinical Research, 145 Kimel Park Drive - Winston-Salem
- Wake Forest University School of Medicine, Medical Center Boulevard - Winston-Salem
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2004-08 |
| Est. Completion | 2008-01 |
| Phase | Phase 2 |
What the finished NCT00349921 record still lists
NCT00349921 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 24 participants, a relatively small participant target, below the 304-participant average among 374 other Pain trials with a reported enrollment target (92% lower).
The record links to 1 condition, with Pain appearing as the primary indexed condition, and to 3 interventions - of which placebo is the first listed.
NCT00349921 reports a single indexed study location in North Carolina.
Frequently Asked Questions
What is clinical trial NCT00349921 about?
NCT00349921 is a clinical study titled "Clonidine Versus Adenosine to Treat Neuropathic Pain". The purpose of this study is to determine the effects of clonidine and adenosine on nerve pain.
What is the current status of trial NCT00349921?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 24 participants. The study started on 2004-08. Estimated completion is 2008-01.
What conditions does trial NCT00349921 study?
This clinical trial studies the following conditions: Pain.
What interventions are being tested in trial NCT00349921?
The interventions under investigation include: placebo (DRUG), adenosine (DRUG), clonidine (DRUG).
Who is sponsoring clinical trial NCT00349921?
This trial is sponsored by Wake Forest University Health Sciences, which has 1,140 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00349921 being conducted?
This trial has 2 study locations across North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Pain
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00349921's enrollment target sits among peer trials
24 325th of 374 higher than 42 of 374 other Pain trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Pain trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Pain Alleviation With Testosterone in Opioid-Induced Hypogonadism
RECRUITING · Phase 2
-
Cannabidiol and Older Adult Cannabis Users
RECRUITING · Phase 2
-
Mechanisms of Cannabidiol in Persons With MS: the Role of Sleep and Pain Phenotype
RECRUITING · Phase 2
-
Neural Correlates of Hypoalgesia Driven by Observation
RECRUITING · Phase 2
-
Cannabis for Palliative Care in Cancer
RECRUITING · Phase 2
-
Pain After Buffered Vs Non Buffered Articaine
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02331979 · 24 participants · NA
Improving Bladder Function in SCI by Neuromodulation
- NCT03096197 · 24 participants · NA
Exoskeleton and Spinal Cord Stimulation for SCI
- NCT03223922 · 24 participants · NA
Neurocognitive Functioning With Genu-Sparing Whole Brain Radiation Therapy for Brain Metastases
- NCT03326921 · 24 participants · Phase 1
HA-1 T TCR T Cell Immunotherapy for the Treatment of Patients With Relapsed or Refractory Acute Leukemia After Donor Stem Cell Transplant
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia